tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Rhythm Biosciences Reports Financial Improvement and Strategic Expansion

Story Highlights
Rhythm Biosciences Reports Financial Improvement and Strategic Expansion

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Rhythm Biosciences Ltd. ( (AU:RHY) ) has shared an announcement.

Rhythm Biosciences Limited reported a significant improvement in its financial performance for the year ending June 2025, with other income from ordinary activities increasing by 91% and losses after tax decreasing by 44%. The incorporation of RHY GeneType Pty Ltd as a wholly-owned subsidiary marks a strategic expansion, potentially enhancing the company’s capabilities in genetic testing and diagnostics.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Limited operates in the biotechnology industry, focusing on the development of medical diagnostics. The company is engaged in creating innovative solutions for early detection of diseases, with a particular emphasis on cancer diagnostics.

Average Trading Volume: 758,844

Technical Sentiment Signal: Buy

Current Market Cap: A$32.92M

For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1